UBX0101
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis, Knee
Conditions
Osteoarthritis, Knee
Trial Timeline
May 16, 2018 → Apr 12, 2019
NCT ID
NCT03513016About UBX0101
UBX0101 is a phase 1 stage product being developed by Unity Biotechnology for Osteoarthritis, Knee. The current trial status is completed. This product is registered under clinical trial identifier NCT03513016. Target conditions include Osteoarthritis, Knee.
What happened to similar drugs?
20 of 20 similar drugs in Osteoarthritis, Knee were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04229225 | Phase 1 | Completed |
| NCT04129944 | Phase 2 | Completed |
| NCT03513016 | Phase 1 | Completed |
Competing Products
20 competing products in Osteoarthritis, Knee